NovoCure
NVCR
219 hedge funds and large institutions have $1.37B invested in NovoCure in 2023 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 84 increasing their positions, 55 reducing their positions, and 50 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 55
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
0.4% less ownership
Funds ownership: 86.43% → 86.03% (-0.4%)
3% less funds holding
Funds holding: 226 → 219 (-7)
8% less capital invested
Capital invested by funds: $1.49B → $1.37B (-$118M)
10% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 50
13% less call options, than puts
Call options by funds: $30.9M | Put options by funds: $35.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$23.7M |
| 2 |
Morgan Stanley
New York
|
+$23.4M |
| 3 |
D.E. Shaw & Co
New York
|
+$13.6M |
| 4 |
BlackRock
New York
|
+$12.4M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$75M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$40.4M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$26.4M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$10.6M |
| 5 |
JFG
Jefferies Financial Group
New York
|
-$7.96M |
NVCR Hedge Fund Activity: Q4 2023 in Review
219 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q4 2023, worth a combined $1.37B — down 7.9% from $1.49B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of NVCR and 45 opened new positions — a net loss of 5 holders — while 55 trimmed existing stakes and 84 added.
The largest buyer was State Street, adding an estimated $23.7M. The largest seller was Capital World Investors, cutting an estimated $75M.
- 219 institutional investors held NovoCure (NVCR) as of Q4 2023, down from 226 in Q3 2023.
- Funds reported $1.37B of NovoCure stock for Q4 2023, down 7.9% quarter-over-quarter.
- 45 funds opened new NovoCure positions in Q4 2023 and 50 closed out, a net change of -5 holders.
- The largest NovoCure buyer in Q4 2023 was State Street, an estimated $23.7M added.
- The largest NovoCure seller in Q4 2023 was Capital World Investors, an estimated $75M sold.
Based on aggregated 13F filings for Q4 2023.